Minjun Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5484093/publications.pdf

Version: 2024-02-01

71 papers	4,398 citations	136950 32 h-index	110387 64 g-index
72 all docs	72 docs citations	72 times ranked	4977 citing authors

#	Article	IF	Citations
1	A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. Drug Discovery Today, 2022, 27, 337-346.	6.4	5
2	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machineÂlearning approach. Archives of Toxicology, 2021, 95, 1793-1803.	4.2	3
3	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341.	3.7	23
4	Machine Learning to Identify Interaction of Single-Nucleotide Polymorphisms as a Risk Factor for Chronic Drug-Induced Liver Injury. International Journal of Environmental Research and Public Health, 2021, 18, 10603.	2.6	4
5	The landscape of hepatobiliary adverse reactions across 53 herbal and dietary supplements reveals immune-mediated injury as a common cause of hepatitis. Archives of Toxicology, 2020, 94, 273-293.	4.2	13
6	Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers. Scientific Reports, 2020, 10, 8188.	3.3	5
7	Editorial: Deep Learning for Toxicity and Disease Prediction. Frontiers in Genetics, 2020, 11, 175.	2.3	4
8	Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI). ALTEX: Alternatives To Animal Experimentation, 2020, 37, 187-196.	1.5	12
9	Predicting the Risks of Drug-Induced Liver Injury in Humans Utilizing Computational Modeling. Challenges and Advances in Computational Chemistry and Physics, 2019, , 259-278.	0.6	0
10	Mode-of-Action-Guided, Molecular Modeling-Based Toxicity Prediction: A Novel Approach for In Silico Predictive Toxicology. Challenges and Advances in Computational Chemistry and Physics, 2019, , 99-118.	0.6	2
11	A Review of Feature Reduction Methods for QSAR-Based Toxicity Prediction. Challenges and Advances in Computational Chemistry and Physics, 2019, , 119-139.	0.6	14
12	Pediatric Intestinal Failureâ€“Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. Journal of Parenteral and Enteral Nutrition, 2018, 42, 455-462.	2.6	9
13	Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regulatory Toxicology and Pharmacology, 2018, 94, 101-107.	2.7	29
14	Review article: therapeutic bile acids and the risks for hepatotoxicity. Alimentary Pharmacology and Therapeutics, 2018, 47, 1623-1638.	3.7	43
15	Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction. Methods in Pharmacology and Toxicology, 2018, , 45-59.	0.2	5
16	Quantitative Structureâ€“Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans. Methods in Pharmacology and Toxicology, 2018, , 77-100.	0.2	16
17	The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Expert Review of Gastroenterology and Hepatology, 2018, 12, 31-38.	3.0	54
18	Target-specific toxicity knowledgebase (TsTKb): a novel toolkit for in silico predictive toxicology. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2018, 36, 219-236.	2.9	6

#	Article	IF	Citations
19	The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity. International Journal of Molecular Sciences, 2018, 19, 2955.	4.1	21
20	The influence of drug properties and host factors on delayed onset of symptoms in drugâ€induced liver injury. Liver International, 2018, 39, 401-410.	3.9	10
21	Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-9-13.	0.0	0
22	Data Mining for Possible Drug-Host Interplay in Clinical Phenotypes of Drug-Induced Liver Injury. Gastroenterology, 2017, 152, S1080-S1081.	1.3	0
23	Influence of host characteristics and pharmacological properties on type of liver injury in hepatotoxicity. Journal of Hepatology, 2017, 66, S401-S402.	3.7	0
24	Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for LiverÂInjury?. Gastroenterology, 2017, 152, 1270-1274.	1.3	18
25	Integrating Drugâ€™s Mode of Action into Quantitative Structureâ€“Activity Relationships for Improved Prediction of Drug-Induced Liver Injury. Journal of Chemical Information and Modeling, 2017, 57, 1000-1006.	5.4	23
26	ArrayTrack: An FDA and Public Genomic Tool. Methods in Molecular Biology, 2017, 1613, 333-353.	0.9	12
27	Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs. Scientific Reports, 2017, 7, 17311.	3.3	84
28	The Influence of Drug Properties and Host Factors on Delayed Onset in Hepatotoxicity. Clinical Therapeutics, 2017, 39, e61-e62.	2.5	0
29	Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. International Journal of Molecular Sciences, 2017, 18, 1335.	4.1	53
30	Drug-Induced Liver Injury. BioMed Research International, 2017, 2017, 1-2.	1.9	7
31	Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans. BioMed Research International, 2016, 2016, 1-20.	1.9	44
32	A Model to predict severity of drugâ€induced liver injury in humans. Hepatology, 2016, 64, 931-940.	7.3	74
33	QSAR Models at the US FDA/NCTR. Methods in Molecular Biology, 2016, 1425, 431-459.	0.9	19
34	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discovery Today, 2016, 21, 648-653.	6.4	248
35	NETBAGs: a network-based clustering approach with gene signatures for cancer subtyping analysis. Biomarkers in Medicine, 2015, 9, 1053-1065.	1.4	9
36	Predicting Hepatotoxicity Using ToxCast in Vitro Bioactivity and Chemical Structure. Chemical Research in Toxicology, 2015, 28, 738-751.	3.3	124

#	Article	IF	Citations
37	Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology, 2015, 63, 503-514.	3.7	319
38	578 Interplay of Gender, Age and Drug Properties in Drug-Induced Liver Injury: Analysis of Adverse Event Reporting at Who Vigibaseâ„¢. Gastroenterology, 2015, 148, S-984.	1.3	0
39	Predicting idiosyncratic drug-induced liver injury â€“ some recent advances. Expert Review of Gastroenterology and Hepatology, 2014, 8, 721-723.	3.0	26
40	High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury. Drug Metabolism and Disposition, 2014, 42, 744-750.	3.3	91
41	Toward predictive models for drug-induced liver injury in humans: are we there yet?. Biomarkers in Medicine, 2014, 8, 201-213.	1.4	124
42	A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the â€˜rule-of-twoâ€™ model. Archives of Toxicology, 2014, 88, 1439-1449.	4.2	54
43	Mining hidden knowledge for drug safety assessment: topic modeling of LiverTox as a case study. BMC Bioinformatics, 2014, 15, S6.	2.6	10
44	A Unifying Ontology to Integrate Histological and Clinical Observations for Drug-Induced Liver Injury. American Journal of Pathology, 2013, 182, 1180-1187.	3.8	23
45	A systems approach for analysis of high content screening assay data with topic modeling. BMC Bioinformatics, 2013, 14, S11.	2.6	19
46	High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology, 2013, 58, 388-396.	7.3	288
47	Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs. Toxicological Sciences, 2013, 136, 242-249.	3.1	96
48	The Liver Toxicity Knowledge Base: A Systems Approach to a Complex End Point. Clinical Pharmacology and Therapeutics, 2013, 93, 409-412.	4.7	76
49	atBioNetâ€“ an integrated network analysis tool for genomics and biomarker discovery. BMC Genomics, 2012, 13, 325.	2.8	33
50	A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science. Toxicological Sciences, 2012, 130, 217-228.	3.1	153
51	Is Toxicogenomics a More Reliable and Sensitive Biomarker than Conventional Indicators from Rats To Predict Drug-Induced Liver Injury in Humans?. Chemical Research in Toxicology, 2012, 25, 122-129.	3.3	57
52	FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discovery Today, 2011, 16, 697-703.	6.4	337
53	Selecting a single model or combining multiple models for microarray-based classifier development? â€“ A comparative analysis based on large and diverse datasets generated from the MAQC-II project. BMC Bioinformatics, 2011, 12, S3.	2.6	13
54	Structural shifts of gut microbiota as surrogate endpoints for monitoring host health changes induced by carcinogen exposure. FEMS Microbiology Ecology, 2010, 73, no-no.	2.7	44

#	Article	IF	Citations
55	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature Biotechnology, 2010, 28, 827-838.	17.5	795
56	Consistency of predictive signature genes and classifiers generated using different microarray platforms. Pharmacogenomics Journal, 2010, 10, 247-257.	2.0	53
57	Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. Pharmacogenomics Journal, 2010, 10, 310-323.	2.0	41
58	Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics Journal, 2010, 10, 267-277.	2.0	54
59	Differential gene expression profiling of mouse skin after sulfur mustard exposure: Extended time response and inhibitor effect. Toxicology and Applied Pharmacology, 2009, 234, 156-165.	2.8	45
60	Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicology and Applied Pharmacology, 2009, 235, 25-32.	2.8	39
61	ebTrack: an environmental bioinformatics system built upon ArrayTrackâ„¢. BMC Proceedings, 2009, 3, S5.	1.6	6
62	Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'. Chinese Medicine, 2008, 3, 3.	4.0	25
63	Mass Spectrometry-Based Metabolic Profiling of Rat Urine Associated with General Toxicity Induced by the Multiglycoside of Tripterygium wilfordii Hook. f.. Chemical Research in Toxicology, 2008, 21, 288-294.	3.3	49
64	Metabolic profiling using combined GC-MS and LC-MS provides a systems understanding of aristolochic acid-induced nephrotoxicity in rat. FEBS Letters, 2007, 581, 707-711.	2.8	104
65	Application of ethyl chloroformate derivatization for gas chromatographyâ€“mass spectrometry based metabonomic profiling. Analytica Chimica Acta, 2007, 583, 277-283.	5.4	151
66	LC/ESI-MS method for the determination of trimetazidine in human plasma: Application to a bioequivalence study on Chinese volunteers. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1804-1807.	2.8	24
67	Metabonomic Study of Aristolochic Acid-Induced Nephrotoxicity in Rats. Journal of Proteome Research, 2006, 5, 995-1002.	3.7	113
68	New perspectives on the Chinese herbal nephropathy. Phytotherapy Research, 2005, 19, 1001-1002.	5.8	1
69	Metabonomic Study on the Biochemical Profiles of A Hydrocortisone-Induced Animal Model. Journal of Proteome Research, 2005, 4, 2391-2396.	3.7	85
70	An Approach to Comparative Analysis of Chromatographic Fingerprints for Assuring the Quality of Botanical Drugs. Journal of Chemical Information and Computer Sciences, 2003, 43, 1068-1076.	2.8	54
71	Genomic Biomarkers for Personalized Medicine in Breast Cancer. International Journal of Clinical Pharmacology & Toxicology, 0, , 35-37.	1.0	1